Nanotechnology Now - Press Release: "Small tools for a big cause: How nanomedicine contributes to better cancer diagnostic and therapy"

Home > Press > Small tools for a big cause: How nanomedicine contributes to better cancer diagnostic and therapy

Nanobiotix NanoXray

Nanobiotix NanoXray

Abstract:
Organizing the Nano World Cancer Day: A European multi-sites event in Paris, Braga and Berlin

In the framework of the World Cancer Day, the European Technology Platform of Nanomedicine (ETPN) and its partners will organize a European event on February the 1st on "How nanomedicine contributes to better cancer diagnostic and therapy". Similar and simultaneous events will be organized in France and Portugal, highlighting the importance of nanomedicine research for cancer on the European level.

Small tools for a big cause: How nanomedicine contributes to better cancer diagnostic and therapy

Paris, Braga and Berlin | Posted on January 31st, 2013

In the framework of the World Cancer Day, the European Technology Platform of Nanomedicine (ETPN) and its partners will organize a European event on February the 1st on "How nanomedicine contributes to better cancer diagnostic and therapy". Similar and simultaneous events will be organized in France and Portugal, highlighting the importance of nanomedicine research for cancer on the European level.

Radiotherapy, chemotherapy and surgery are part of the therapeutic arsenal for patients with cancer. New technologies associated with nanoparticles could provide more effective solutions to personalize diagnoses and treat these diseases, while improving targeted drug delivery and reducing side effects and collateral damages on the body. These breakthrough therapies based on nanomedicine are already a reality with concrete results, 60 nano-products on the market and more than 70 in the pipeline. Nanomedicine can go further in bringing new therapeutic mode of action into cells. For instance, nanoparticles can already be injected into the tumor and then be activated to produce a physical effect and destroy cancer cells locally.

In the press events across Europe, leading international stakeholders in the field will introduce examples highlighting the key role of nanomedicine for cancer therapy, diagnoses and imaging.

This year, these stakeholders across Europe who have already confirmed are:

National Cancer organizations: Canceropole CLARA (FR)
Comprehensive Cancer Center (Charité University Hospital) (DE)
Instituto Português de Oncologia do Porto (PT)
SMEs: Nanobiotix (FR)

Universities / Public laboratories: Thomas Jefferson University, Philadelphia (US), CNRS / Paris 11 University (FR), Ludwig-Maximilians University München (DE), Aachen University Hospital (DE), INL - International Iberian Nanotechnology Laboratory (Portugal-Spain), Universidad de Santiago de Compostela (Spain), University of Lisboa/ Faculty of Pharmacy (PT).

Leading local experts involved in the Berlin Press event:

- Professor Reinhold Schäfer, Head of the Laboratory of Molecular Tumor Pathology, Comprehensive Cancer Center, Charité University Hospital, Berlin

- Bernd Muehlenweg, Representative of the ETP Nanomedicine and of Nanobiotix, Paris/Hamburg

- Dr Manfred Ogris, Department of Pharmacy, Ludwig-Maximilians University München, Munich

- Dr Twan Lammers, Department of Experimental Molecular Imaging, Aachen University Hospital, Aachen

This conference will give an overview on nanomedicine for cancer: What are the key areas of research? What are the new methods of diagnosis? What are the new treatments in development? What are the first results? What are the products used every day?

####

About VDI/VDE-Innovation + Technik GmbH
For High Tech to become a success story, VDI/VDE Innovation + Technik GmbH (VDI/VDE-IT) has been working hard for more than 25 years to be a reliable partner of industry and research and of the political community. With our fields of activity - Research Funding, Technology Politics and Innovation Management – we are covering the entire spectrum of the innovation process, from research through application all the way to the introduction and use of new technologies.

Our customers at home and abroad wish to implement innovations in the high-tech sector. Bringing our knowledge and experience to bear in important key technologies such as microsystems engineering, bio and nano technology and the multimedia, we assist our clients in translating their ideas into action, helping them to make their high-tech projects a success. With this objective in mind, our multidisciplinary team of over 100 experts in the natural and social sciences, engineers, and economists are continuously developing new ideas and methods, tailor-made to the personal needs of our customers.

VDI/VDE Innovation + Technik GmbH is a society of VDI GmbH and of VDE (Association for Electrical, Electronic & Information Technologies).

ABOUT ETP Nanomedicine

The European Technology Platform Nanomedicine was established in 2005 as a joint venture of the European Commission and CEOs of large industrial companies such as Philips, Siemens and UCB, SMEs and academic research institutions to investigate and advance joint activities in the area of nanotechnology in medicine. Since 2005 the ETPN published a number of strategic documents outlining the needs and roadmaps for nanomedicine research in Europe. The ETPN contributed to set up numerous European funded projects providing a first impression of the conditions for a suitable social and economic environment and the structural requirements for an efficient translation of R&D results into innovative nanomedicine. The ETPN supports its members in coordinating their joint research efforts and improving communication amongst the members as well as towards the European Commission and the European Member States.
www.etp‐nanomedicine.eu

For more information, please click here

Contacts:
Wiebke Ehret
+49 30 310078-125

Contact Nano World Cancer Day
Secretariat ETPN
Olivier Fontaine
Tel: +49 30 310078-413

Local Press Contact Berlin
VDI/VDE-IT
Christoph Schmale